
NFATc1-IN-1
CAS No. 1912422-56-0
NFATc1-IN-1( —— )
Catalog No. M35568 CAS No. 1912422-56-0
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 45 | Get Quote |
![]() ![]() |
10MG | 76 | Get Quote |
![]() ![]() |
25MG | 150 | Get Quote |
![]() ![]() |
50MG | 227 | Get Quote |
![]() ![]() |
100MG | 335 | Get Quote |
![]() ![]() |
500MG | 782 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameNFATc1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionNFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM.
-
DescriptionNFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research.
-
In VitroNFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption.NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1Cell Viability Assay Cell Line:Osteoclast precursor RAW 264.7 cells Concentration:0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time:4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.Immunofluorescence Cell Line:RAW264.7 cells Concentration:1.5 or 2.5 μM Incubation Time:24 h Result:Blocked NFATc1 nuclear translocation and decreased the level of NFATc1.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorRANKL/RANK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1912422-56-0
-
Formula Weight375.11
-
Molecular FormulaC13H8F2INO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (333.24 mM; Ultrasonic )
-
SMILESC(NC1=C(F)C=C(I)C=C1)(=O)C2=C(O)C=CC(F)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 Jul 19;117:70-84.?
molnova catalog



related products
-
Yubeinine
Yubeinine is an alkaloid natural product possessing tracheal relaxant effects.
-
Aficamten
Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.
-
Azido-PEG9-alcohol
Azido-PEG9-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.